Abbott's Volt PFA System Receives FDA Approval, Entering Competitive U.S. Market Against Medtronic, Boston Scientific, and Johnson & Johnson

December 22, 2025Abbott Announces FDA Approval of Its Volt Pulse Field Ablation (PFA) SystemThis approval marks Abbott's official entry into the U.S. PFA market, where it will compete head-to-head with companies such as Medtronic, Boston Scientific, and Johnson & Johnson Medical Technologies.

The Volt PFA System is an important extension of Abbott's electrophysiology product line, featuring an integrated design that enables doctors to perform cardiac mapping, pacing, and ablation using the same catheter. Its unique balloon-basket design supports multiple operating modes, facilitating ease of use and efficient energy delivery, allowing precise targeting of energy to the intended tissue to terminate abnormal electrical signals in the heart.

The approval of this system is based on the positive data from the VOLT-AF IDE clinical study. The study was conducted across 40 centers in the U.S., Europe, Canada, and Australia, enrolling a total of 392 patients. The results showed,In patients with paroxysmal atrial fibrillation (PAF), the Volt PFA system demonstrates clinically meaningful safety and efficacy.

DJ Lakkireddy, MD, Executive Medical Director of the Kansas City Heart Rhythm Institute and one of the first doctors in the U.S. to use the system, stated: "Atrial fibrillation is a progressive disease, and timely intervention is crucial for controlling the condition and improving patients' quality of life."The real-time contact visualization and balloon basket design of the Volt system can provide better tissue contact and more precise energy delivery, while overcoming some limitations of earlier PFA systems.”

Christopher Piorkowski, M.D., Chief Medical Officer of Abbott's electrophysiology business, added: "Volt System Allows Patients to Undergo Surgery Under Conscious Sedation Without General Anesthesia", providing new options for many patients and helping to reduce recovery time and surgery time."

This system can be integrated with Abbott's EnSite™ X EP system to achieve precise 3D cardiac mapping, reduce intraoperative catheter changes, and thereby improve surgical efficiency. Its design goal is to achieve lasting lesions with fewer pulses, reducing the risk of repeat ablation and complications.

Industry analysis shows that competition in the PFA field is becoming increasingly fierce. Global sales of Boston Scientific's Farapulse system have exceeded $1 billion in 2024, while Medtronic's PFA product saw a year-over-year sales increase of over 300% in the second fiscal quarter. Johnson & Johnson is also continuously strengthening its position in this area. There were previous concerns that Abbott's electrophysiology business might face competitive pressure from early movers. However, the recent approval of Volt validates Abbott’s strategy of achieving market breakthroughs through technological innovation.

BTIG Analysts Maintain "Buy" Rating for AbbottIt was noted that the approval time was slightly earlier than expected.And look forward to more data from the VOLT-AF IDE study being released at relevant academic conferences in 2026.

With the approval and market launch of the Volt PFA system, Abbott's presence in the pulsed field ablation sector deepens further, introducing a new dynamic to the competitive landscape of the industry.